Search | IOVS | ARVO Journals

Showing 1 – 20 of 138

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Leber’s Hereditary Optic Neuropathy visual field loss characterization by machine learning

Alice Galzignato; Catarina Coutinho; Ferdinando Zanchetta; Michele Carbonelli; Marco Battista; Giulia Amore; Valerio Carelli; Luigi Brotto; Paolo Nucci; Lisa Checchin; Giacomo Savini; Francesco Bandello; Chiara La Morgia; Maria Lucia Cascavilla; Rita Fioresi; Piero Barboni

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):87.

ARVO Annual Meeting Abstract June 2024

Assessment of Visual Field Loss Progression for DOA and Wolfram Syndrome employing a DOA- OPA1 Archetypal Analysis Model

Catarina Coutinho; Ferdinando Zanchetta; Michele Carbonelli; Alice Galzignato; Marco Battista; Giulia Amore; Valerio Carelli; Luigi Brotto; Paolo Nucci; Lisa Checchin; Giacomo Savini; Francesco Bandello; Chiara La Morgia; Rita Fioresi; Maria Lucia Cascavilla; Piero Barboni

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):86.

ARVO Annual Meeting Abstract June 2024

Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy in the Real-Life Setting

Jose Alain Sahel; Catherine Vignal-Clermont; Valerio Carelli; Chiara La Morgia; Mark L. Moster; Robert C Sergott; Sean P. Donahue; Helene Dollfus; Thomas Klopstock; Rabih Hage; Vasily Smirnov; Catherine Cochard; Francis Munier; Pauline Zoppe; Magali Taiel; Patrick Yu-Wai-Man

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):419.

ARVO Annual Meeting Abstract June 2024

Treatment Options For Acute/Subacute Patients With m.11778G>A MT-ND4 Leber Hereditary Optic Neuropathy: A Meta-Analysis

Patrick Yu-Wai-Man; Nancy J. Newman; Valerio Carelli; Valerie Biousse; Catherine Vignal-Clermont; François Montestruc; Magali Taiel; Jose Alain Sahel

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):416.

ARVO Annual Meeting Abstract June 2024

Ocular Post-Mortem Analyses with Histopathological and Molecular Assessments in LHON Following AAV2 Gene Therapy

Valerio Carelli; Nancy J. Newman; Leonardo Caporali; Fred Ross-Cisneros; Elisa Boschetti; Valerie Biousse; Lindreth DuBois; Henry Liu; Philippe Ancian; Magali Taiel; Alfredo A Sadun

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6083.

ARVO Annual Meeting Abstract June 2024

Optic nerve edema and pseudo-edema differentiation analysis using automated segmentation of fiber layer and blood vessels

Marco Battista; Jonathan Oakley; Michele Carbonelli; Catarina Coutinho; Alice Galzignato; Luigi Brotto; Giulia Amore; Lisa Checchin; Paolo Nucci; Leonardo Bottazzi; Valerio Carelli; Francesco Bandello; Chiara La Morgia; Maria Lucia Cascavilla; Piero Barboni

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):99.

ARVO Annual Meeting Abstract June 2024

Visual acuity outcomes by causative mutation in Leber hereditary optic neuropathy: Analysis of historical data from CRS-2

Judith van Everdingen; Bart Peter Leroy; Patrick Yu-Wai-Man; Maciej Krawczynski; Costanza Lamperti; Valerio Carelli; Xavier Llòria; Thomas Klopstock

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):OD11.

ARVO Annual Meeting Abstract June 2024

Long-term safety of idebenone in patients with Leber hereditary optic neuropathy: Results from the PAROS study

Berthold Pemp; Thomas Klopstock; Xavier Llòria; Valerio Carelli

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):OD31.

ARVO Annual Meeting Abstract June 2023

Studying Leber hereditary optic neuropathy with induced pluripotent stem cells

Valerio Carelli

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):1344.

ARVO Annual Meeting Abstract June 2023

Use of lenadogene nolparvovec gene therapy for Leber hereditary optic neuropathy in early access programs

Chiara La Morgia; Catherine Vignal-Clermont; Valerio Carelli; Rabih Hage; Mark L. Moster; Robert C Sergott; Sean P Donahue; Patrick Yu-Wai-Man; Hélène Dollfus; Thomas Klopstock; Vasily M. SMIRNOV; Catherine Cochard; Claudia Prospero Ponce; Francis Munier; Magali Taiel; Jose Sahel

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):1956.

ARVO Annual Meeting Abstract June 2023

Treatment with lenadogene nolparvovec gene therapy results in sustained visual improvement in m.11778G>A MT-ND4 -LHON patients: the RESTORE study

Patrick Yu-Wai-Man; Nancy J Newman; Biousse Valérie; Valerio Carelli; Mark L. Moster; Catherine Vignal-Clermont; Thomas Klopstock; Alfredo A. Sadun; Robert C Sergott; Magali Taiel; José-Alain Sahel

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):1955.

ARVO Annual Meeting Abstract June 2023

Long-term efficacy of idebenone in patients with LHON according to age at onset and disease phase: Results from the LEROS study

Livia Tomasso; Valerio Carelli; Chiara La Morgia; Patrick Yu-Wai-Man; Xavier Llòria; Thomas Klopstock

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):1953.

ARVO Annual Meeting Abstract June 2023

Visual outcome in Leber’s hereditary optic neuropathy with asynchronous onset

Michele Carbonelli; Martina Romagnoli; Chiara La Morgia; Giulia Amore; Piero Barboni; Valerio Carelli

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4110.

ARVO Annual Meeting Abstract June 2023

Neuro-ophthalmological phenotype and correlations with heteroplasmy levels in MELAS and MERRF.

Giulia Amore; Michele Carbonelli; Martina Romagnoli; Fiorini Claudio; Leonardo Caporali; Chiara La Morgia; Valerio Carelli

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4107.

ARVO Annual Meeting Abstract June 2023

Optic nerve head morphology as biomarker in Leber hereditary optic neuropathy (LHON)

Alice Galzignato; Jonathan Oakley; Maria Lucia Cascavilla; Catarina P. Coutinho; Michele Carbonelli; Marco Battista; Alessandro Berni; Giorgio Lari; Giulia Amore; Chiara La Morgia; Enrico Borrelli; Francesco Bandello; Valerio Carelli; Piero Barboni

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4093.

ARVO Annual Meeting Abstract June 2023

New genotype-phenotype correlations in recessive Leber hereditary optic neuropathy

Piero Barboni; Marco Battista; Leonardo Caporali; Enrico Borrelli; Giorgio Lari; Lisa Checchin; Alessandro Berni; Alice Galzignato; claudio fiorini; Paolo Nucci; Francesco Bandello; Valerio Carelli; Maria Lucia Cascavilla

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4090.

ARVO Annual Meeting Abstract June 2023

Peripapillary Hyperreflective Ovoid Mass-like Structures (PHOMS) in Patients with Acute Leber’s Hereditary Optic Neuropathy

Maria Lucia Cascavilla; Enrico Borrelli; Marco Battista; Giorgio Lari; Stefano Albertini; Anna Maria De Negri; Catarina Coutinho; Alice Galzignato; Chiara La Morgia; Guido Ricciotti; Michele Carbonelli; Valerio Carelli; Francesco Bandello; Piero Barboni

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4088.

ARVO Annual Meeting Abstract June 2023

Leber Hereditary Optic Neuropathy (LHON): Online medical education can significantly improve physicians’ diagnostic competence and confidence, and improve therapy knowledge

Siggi Trier; Gillian Griffith; Karen Reid; Patrick Yu-Wai-Man; Valerio Carelli; Thomas Klopstock; Bart Peter Leroy; Nancy J Newman; Catherine Vignal-Clermont

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4079.

ARVO Annual Meeting Abstract June 2022

The phase III REFLECT trial: efficacy of bilateral gene therapy for Leber hereditary optic neuropathy (LHON) is maintained 2 years post administration

Patrick Yu-Wai-Man; Nancy Newman; Prem S Subramanian; Mark Moster; An-Guor Wang; Sean Donahue; Bart Leroy; Valerio Carelli; Valerie Biousse; Catherine Vignal-Clermont; Alfredo A Sadun; Gema Fernandez; Elizabeth Fortin; Rudrani Banik; Magali Taiel; Jose Alain Sahel

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):434.

Eye Movements, Strabismus, Amblyopia and Neuro-ophthalmology January 2022

Longitudinal Study of Optic Disk Perfusion and Retinal Structure in Leber's Hereditary Optic Neuropathy

PDF

Giacomo Calzetti; Chiara La Morgia; Marco Cattaneo; Arturo Carta; Francesca Bosello; Giulia Amore; Michele Carbonelli; Maria Lucia Cascavilla; Stefano Gandolfi; Valerio Carelli; Leopold Schmetterer; Hendrik P. N. Scholl; Piero Barboni
TAGS: longitudinal studies, optic atrophy, hereditary, leber, optic disk, perfusion, retina, vascular flow
Invest. Ophthalmol. Vis. Sci.. 2022; 63(1):43. https://doi.org/10.1167/iovs.63.1.43

Includes: Supplemental Content

1 2 3 4 5

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Leber’s Hereditary Optic Neuropathy visual field loss characterization by machine learning

Assessment of Visual Field Loss Progression for DOA and Wolfram Syndrome employing a DOA- OPA1 Archetypal Analysis Model

Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy in the Real-Life Setting

Treatment Options For Acute/Subacute Patients With m.11778G>A MT-ND4 Leber Hereditary Optic Neuropathy: A Meta-Analysis

Ocular Post-Mortem Analyses with Histopathological and Molecular Assessments in LHON Following AAV2 Gene Therapy

Optic nerve edema and pseudo-edema differentiation analysis using automated segmentation of fiber layer and blood vessels

Visual acuity outcomes by causative mutation in Leber hereditary optic neuropathy: Analysis of historical data from CRS-2

Long-term safety of idebenone in patients with Leber hereditary optic neuropathy: Results from the PAROS study

Studying Leber hereditary optic neuropathy with induced pluripotent stem cells

Use of lenadogene nolparvovec gene therapy for Leber hereditary optic neuropathy in early access programs

Treatment with lenadogene nolparvovec gene therapy results in sustained visual improvement in m.11778G>A MT-ND4 -LHON patients: the RESTORE study

Long-term efficacy of idebenone in patients with LHON according to age at onset and disease phase: Results from the LEROS study

Visual outcome in Leber’s hereditary optic neuropathy with asynchronous onset

Neuro-ophthalmological phenotype and correlations with heteroplasmy levels in MELAS and MERRF.

Optic nerve head morphology as biomarker in Leber hereditary optic neuropathy (LHON)

New genotype-phenotype correlations in recessive Leber hereditary optic neuropathy

Peripapillary Hyperreflective Ovoid Mass-like Structures (PHOMS) in Patients with Acute Leber’s Hereditary Optic Neuropathy

Leber Hereditary Optic Neuropathy (LHON): Online medical education can significantly improve physicians’ diagnostic competence and confidence, and improve therapy knowledge

The phase III REFLECT trial: efficacy of bilateral gene therapy for Leber hereditary optic neuropathy (LHON) is maintained 2 years post administration

Longitudinal Study of Optic Disk Perfusion and Retinal Structure in Leber's Hereditary Optic Neuropathy

To View More...

You must be signed into an individual account to use this feature.